J. Goldman

Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small cell lung cancer: a pooled analysis.

K. O'Byrne, S. Ramalingam, M. Hellmann, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN

H. Mann, M. Hochmair, L. Havel, 2022, ESMO open.

387P Telisotuzumab vedotin (Teliso-V) in combination with osimertinib in patients with advanced EGFR-mutated, c-met overexpressing, non-small cell lung cancer (NSCLC): Safety and efficacy results from phase Ib study

D. Camidge, P. Tomasini, M. Dunbar, 2022, Annals of Oncology.

1239P ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib

J. Riess, B. Cho, I. Okamoto, 2021, Annals of Oncology.

LBA47 Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA

F. de Marinis, C. Grohé, Y. Wu, 2022, Annals of Oncology.

Abstract 4716: A first-in-human phase 1 study to evaluate the MEK1/2 inhibitor GDC-0973 administered daily in patients with advanced solid tumors

B. Sikic, P. LoRusso, W. Ma, 2011 .

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial

S. Loi, M. Burkard, R. Bose, 2023, Annals of Oncology.